Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (879 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
A disorder of immunoglobulin synthesis in which large quantities of abnormal heavy chains are excreted in the urine. The amino acid sequences of the N-(amino-) terminal regions of these chains are normal, but they have a deletion extending from part of the variable domain through the first domain of the constant region, so that they cannot form cross-links to the light chains. The defect arises through faulty coupling of the variable (V) and constant (C) region genes.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Heavy Chain Diseases; gamma-Chain Disease; gamma Chain Disease; gamma-Chain Diseases; Franklin Disease; Franklin's Disease; Franklins Disease; mu-Chain Disease.
Where it fits in the MeSH classification
- Broader topics
- Paraproteinemias; Lymphoproliferative Disorders
- Narrower topics
- Immunoproliferative Small Intestinal Disease
- See also
- Immunoglobulin Heavy Chains
Research landscape
PubMed indexes 1,000 records tagged with the MeSH heading “Heavy Chain Disease” (counts retrieved 2026-10-29). 36 of them (3.6%) were published from 2020 onward, and the busiest period so far is through 1999 with 793 records.
Reviews account for 156 records (15.6%) and meta-analyses for 1. Randomized controlled trials number 0 (0.0%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 793 |
| 2000-2009 | 82 |
| 2010-2019 | 89 |
| 2020 onward | 36 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 156 | 15.6% |
| Meta-analyses | 1 | 0.1% |
| Randomized controlled trials | 0 | 0.0% |
Method: PubMed query "Heavy Chain Disease"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in immunology
Immune responses are studied in model organisms, in cells from donors and in patients, and the same pathway can behave differently across these settings. Mouse immune systems differ from human ones in important ways, and blood measurements may not reflect what happens in tissues. Clinical conclusions about immune-mediated disease or immunotherapy come mainly from controlled trials and long-term cohorts. Check the species and tissue studied, whether markers were linked to outcomes patients notice, and the follow-up time.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
Widespread intronic polyadenylation diversifies immune cell transcriptomes [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Alternative cleavage and polyadenylation (ApA) is known to alter untranslated region (3'UTR) length but can also recognize intronic polyadenylation (IpA) signals to generate transcripts that lose part or all of the coding region.
- Closing excerpt
- MM cells display a striking loss of IpA isoforms expressed in plasma cells, associated with shorter progression-free survival and impacting key genes in MM biology and response to lenalidomide.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (145 words)
Alternative cleavage and polyadenylation (ApA) is known to alter untranslated region (3'UTR) length but can also recognize intronic polyadenylation (IpA) signals to generate transcripts that lose part or all of the coding region. We analyzed 46 3'-seq and RNA-seq profiles from normal human tissues, primary immune cells, and multiple myeloma (MM) samples and created an atlas of 4927 high-confidence IpA events represented in these cell types. IpA isoforms are widely expressed in immune cells, differentially used during B-cell development or in different cellular environments, and can generate truncated proteins lacking C-terminal functional domains. This can mimic ectodomain shedding through loss of transmembrane domains or alter the binding specificity of proteins with DNA-binding or protein-protein interaction domains. MM cells display a striking loss of IpA isoforms expressed in plasma cells, associated with shorter progression-free survival and impacting key genes in MM biology and response to lenalidomide.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 29712909 · DOI · PMC5928244
Screening differentially expressed genes between endometriosis and ovarian cancer to find new biomarkers for endometriosis [2]
Abstract reading summary — source excerpts
- Opening excerpt
- AimEndometriosis is one of the most common reproductive system diseases, but the mechanisms of disease progression are still unclear.
- Closing excerpt
- We screened relevant therapeutic agents for target genes in the drug database, and performed histological validation of target genes with both expression and survival analysis difference in cancer databases.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (296 words)
AimEndometriosis is one of the most common reproductive system diseases, but the mechanisms of disease progression are still unclear. Due to its high recurrence rate, searching for potential therapeutic biomarkers involved in the pathogenesis of endometriosis is an urgent issue.MethodsDue to the similarities between endometriosis and ovarian cancer, four endometriosis datasets and one ovarian cancer dataset were downloaded from Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified, followed by gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and protein-protein interaction (PPI) analyses. Then, we validated gene expression and performed survival analysis with ovarian serous cystadenocarcinoma (OV) datasets in TCGA/GTEx database, and searched for potential drugs in the Drug-Gene Interaction Database. Finally, we explored the miRNAs of key genes to find biomarkers associated with the recurrence of endometriosis.ResultsIn total, 104 DEGs were identified in the endometriosis datasets, and the main enriched GO functions included cell adhesion, extracellular exosome and actin binding. Fifty DEGs were identified between endometriosis and ovarian cancer datasets including 11 consistently regulated genes, and nine DEGs with significant expression in TCGA/GTEx. Only IGHM had both significant expression and an association with survival, three module DEGs and two significantly expressed DEGs had drug associations, and 10 DEGs had druggability.ConclusionsITGA7, ITGBL1 and SORBS1 may help us understand the invasive nature of endometriosis, and IGHM might be related to recurrence; moreover, these genes all may be potential therapeutic targets.KEY MESSAGEThis manuscript used a bioinformatics approach to find target genes for the treatment of endometriosis.This manuscript used a new approach to find target genes by drawing on common characteristics between ovarian cancer and endometriosis.We screened relevant therapeutic agents for target genes in the drug database, and performed histological validation of target genes with both expression and survival analysis difference in cancer databases.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34409913 · DOI · PMC8381947
The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and Clinical Outcome in Acute Lymphoblastic Leukemia [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Precursor-B cell receptor (pre-BCR) signaling represents a crucial checkpoint at the pre-B cell stage.
- Closing excerpt
- Our findings suggest that BCP-ALL are arrested at different cellular stages, which relates to the expression pattern of the pre-BCR components that could serve as prognostic markers for high-risk pediatric BCP-ALL patients.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (199 words)
Precursor-B cell receptor (pre-BCR) signaling represents a crucial checkpoint at the pre-B cell stage. Aberrant pre-BCR signaling is considered as a key factor for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) development. BCP-ALL are believed to be arrested at the pre-BCR checkpoint independent of pre-BCR expression. However, the cellular stage at which BCP-ALL are arrested and whether this relates to expression of the pre-BCR components (IGHM, IGLL1 and VPREB1) is still unclear. Here, we show differential protein expression and copy number variation (CNV) patterns of the pre-BCR components in pediatric BCP-ALL. Moreover, analyzing six BCP-ALL data sets (n = 733), we demonstrate that TCF3-PBX1 ALL express high levels of IGHM, IGLL1 and VPREB1, and are arrested at the pre-B stage. By contrast, ETV6-RUNX1 ALL express low levels of IGHM or VPREB1, and are arrested at the pro-B stage. Irrespective of subtype, ALL with high levels of IGHM, IGLL1 and VPREB1 are arrested at the pre-B stage and correlate with good prognosis in high-risk pediatric BCP-ALL (n = 207). Our findings suggest that BCP-ALL are arrested at different cellular stages, which relates to the expression pattern of the pre-BCR components that could serve as prognostic markers for high-risk pediatric BCP-ALL patients.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 27611867 · DOI · PMC5017602
Novel Laboratory Approaches in Heavy Chain Disease With Discordant Immunoglobulin Quantitation: A Case Report and Literature Review [4]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundHeavy chain disease (HCD) is a rare plasma-cell neoplasm frequently linked to lymphoproliferative and autoimmune disorders.
- Closing excerpt
- This is necessary to ensure prompt and effective care for a rare condition, particularly with complex presentations like this case.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (239 words)
BackgroundHeavy chain disease (HCD) is a rare plasma-cell neoplasm frequently linked to lymphoproliferative and autoimmune disorders. Clinical presentation varies widely, with no conventional signs or symptoms. The prognosis is frequently uncertain, and there is currently no typical diagnosis or treatment. Truncated immunoglobulins' heavy chains (HCs) identification and bound light chains (LCs) exclusion are diagnostic requirements. The initial approach is laboratory-based, mostly from protein analysis, as serum protein electrophoresis (SPE), immunotyping (IT), and immunofixation (IFE) are usually the first diagnostic steps.MethodsA panel of tests resulted in low serum protein, so SPE, IT, and IFE were conducted. The findings established a spike's presence and γ-HC isotype, but differential diagnosis from gammopathies with LCs' low reactivity to reagents required further testing. Consequently, a molecular weight separation gel and immunoselection were executed.ResultsSPE showed a 29.4% (12.9 g/L) spike central to the γ-fraction, while IT resulted in a subtraction in the IgG window, later verified by serum IFE. Immunoselection showed no LC-HC link, excluding a gammopathy with difficult LC identification. The molecular weight gel revealed a 160 kDa band. This rare case of HCD presents unique complexity, also due to discordant IgG3-IgG quantitation, associated angioimmunoblastic lymphoma morphology, and EBV genome.ConclusionThe aim is to draw attention to the difficulties in diagnosing HCD and stress the importance of both advanced methods and a proper laboratory approach. This is necessary to ensure prompt and effective care for a rare condition, particularly with complex presentations like this case.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41856916 · DOI · PMC13163937
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease [5]
- Research article Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases [6]
- Research article Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms [7]
- Research article Heavy chain diseases: current findings and concepts [8]
- Research article Pathological study of alpha-chain disease, with special emphasis on evolution [9]
- Research article Alpha-chain disease. Pathogenesis and relation to Mediterranean lymphoma [10]
References
- Singh I, Lee SH, Sperling AS, Samur MK, Tai YT, Fulciniti M, et al.. Widespread intronic polyadenylation diversifies immune cell transcriptomes. . 2018. PMID 29712909 · DOI · PMC5928244
- Lu Z, Gao Y. Screening differentially expressed genes between endometriosis and ovarian cancer to find new biomarkers for endometriosis. . 2021. PMID 34409913 · DOI · PMC8381947
- Chen D, Zheng J, Gerasimcik N, Lagerstedt K, Sjögren H, Abrahamsson J, et al.. The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and Clinical Outcome in Acute Lymphoblastic Leukemia. . 2016. PMID 27611867 · DOI · PMC5017602
- Longhi E, Çeka A, Olivieri F, Moretti M, Sabbatinelli J. Novel Laboratory Approaches in Heavy Chain Disease With Discordant Immunoglobulin Quantitation: A Case Report and Literature Review. . 2026. PMID 41856916 · DOI · PMC13163937
- Buxbaum J. Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am. 1992. PMID 1582976 · DOI
- Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am. 1999. PMID 10626147 · DOI
- Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood. 2005. PMID 15542584 · DOI
- Seligmann M, Mihaesco E, Preud'homme JL, Danon F, Brouet JC. Heavy chain diseases: current findings and concepts. Immunol Rev. 1979. PMID 121099 · DOI
- Galian A, Lecestre MJ, Scotto J, Bognel C, Matuchansky C, Rambaud JC. Pathological study of alpha-chain disease, with special emphasis on evolution. Cancer. 1977. PMID 404026 · DOI
- Rambaud JC, Matuchansky C. Alpha-chain disease. Pathogenesis and relation to Mediterranean lymphoma. Lancet. 1973. PMID 4122995 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.